DJIA 16,129.40 -245.36 -1.50%
NASDAQ 4,693.14 -40.36 -0.85%
S&P 500 1,924.15 -26.98 -1.38%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)

87.44 -0.31 (-0.35%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MDVN $87.44 -0.35%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $86.78
Previous Close $87.74
Daily Range $86.39 - $88.87
52-Week Range $80.01 - $141.58
Market Cap $7.1B
P/E Ratio 26.83
Dividend (Yield) $0.00 (0.0%)
Volume 291,860
Average Daily Volume 1,316,620
Current FY EPS $1.94

Sector

Healthcare

Industry

Drug Makers

Medivation, Inc. (MDVN) Description

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies. Website: http://www.medivation.net/

News & Commentary

3 Biotech Stocks We Love

Our analysts can't help but fall in love with these three biotech stocks.

Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?

Benzinga's Top Initiations

Medivation Destined To Become A Biotech Behemoth As Low-Risk Pipeline Expands

Medivation Destined To Become Biotech Behemoth As Low Risk Pipeline Expands

Medivation to Gain Global Rights to BioMarin's Talazoparib

Biomarin Goes For Pragmatism As The Markets Dip

Benzinga's M&A Chatter for Monday August 24, 2015

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talaz

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

Patent Claims To Xtandi Seem Weak

See More MDVN News...

MDVN's Top Competitors

MDVN $87.44 (-0.35%)
Current stock: MDVN
TMO $121.31 (-1.19%)
Current stock: TMO
ILMN $192.51 (-1.50%)
Current stock: ILMN
WAT $120.78 (-1.54%)
Current stock: WAT